Edwards Lifesciences (NYSE:EW) Releases Earnings Results, Beats Expectations By $0.04 EPS

Edwards Lifesciences (NYSE:EW) posted its earnings results on Tuesday. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04, Zacks reports. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences updated its FY 2025 guidance to 2.400-2.500 EPS and its Q1 2025 guidance to 0.580-0.640 EPS.

Edwards Lifesciences Stock Down 0.2 %

Shares of EW stock traded down $0.15 during mid-day trading on Tuesday, hitting $70.95. The company’s stock had a trading volume of 3,405,627 shares, compared to its average volume of 4,396,275. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12. The business has a 50-day moving average price of $72.46 and a 200 day moving average price of $69.26. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market cap of $41.85 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 3.64 and a beta of 1.10.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,000 shares of company stock worth $547,430 over the last quarter. 1.29% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Piper Sandler cut their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Robert W. Baird cut their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Finally, Barclays increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.